Обзорная статья

CAR-NK cells: A promising cellular immunotherapy for cancer

Guozhu XieKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USAHan DongDepartment of Cancer Immunology and Virology, Dana-Farber Cancer Institute, Boston, MA 02115, USA; Department of Microbiology and Immunology, Harvard Medical School, Boston, MA 02115, USAYong LiangDivision of Hematologic Malignancies and Transplantation, Dana Farber Cancer Institute, Boston, MA 02115, USAJames Dongjoo HamKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USARomee RizwanDivision of Hematologic Malignancies and Transplantation, Dana Farber Cancer Institute, Boston, MA 02115, USA. Electronic address: [email protected]Jianzhu ChenKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA. Electronic address: [email protected]

2020en

ABI

Аннотация

cytotoxic T cells are two types of immune cells that can kill target cells through similar cytotoxic mechanisms. With the remarkable success of chimeric antigen receptor (CAR)-engineered T (CAR-T) cells for treating haematological malignancies, there is a rapid growing interest in developing CAR-engineered NK (CAR-NK) cells for cancer therapy. Compared to CAR-T cells, CAR-NK cells could offer some significant advantages, including: (1) better safety, such as a lack or minimal cytokine release syndrome and neurotoxicity in autologous setting and graft-versus-host disease in allogenic setting, (2) multiple mechanisms for activating cytotoxic activity, and (3) high feasibility for 'off-the-shelf' manufacturing. CAR-NK cells could be engineered to target diverse antigens, enhance proliferation and persistence in vivo, increase infiltration into solid tumours, overcome resistant tumour microenvironment, and ultimately achieve an effective anti-tumour response. In this review, we focus on recent progress in genetic engineering and clinical application of CAR-NK cells, and discuss current challenges and future promise of CAR-NK cells as a novel cellular immunotherapy in cancer.

Перевод пока недоступен

Идентификаторы

DOI: 10.1016/j.ebiom.2020.102975

Цитирования и источники

Цитирований: 3Использованных источников: 0

Показатели — AkademScholar